Skip to main content
. 2015 Jun 4;2(2):119–130. doi: 10.3233/JND-150081

Fig.3.

Fig.3

Distribution of the alteration of MS AR in response to VPA. In this study, we have arbitrarily defined “responders” as individuals whose MS AR increased by at least 15% after 6 months of VPA to account for the possibility that a subgroup of individuals in the VALIANT trial might be resistant to the effects of VPA. By this definition, approximately 71% of the subjects wereresponders.